Reata Pharms Drug Patent Portfolio
Reata Pharms owns 1 orange book drug protected by 7 US patents Given below is the list of Reata Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8993640 | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof | 24 Apr, 2033 | Active |
| US9701709 | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof | 24 Apr, 2033 | Active |
| US8124799 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | 03 Dec, 2029 | Active |
| US11091430 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 | 20 Apr, 2029 | Active |
| US11919838 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | 20 Apr, 2029 | Active |
| US8440854 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino acid and other modifications at C-17 | 20 Apr, 2029 | Active |
| US9670147 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | 20 Apr, 2029 | Active |
Latest Legal Activities on Reata Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Reata Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Second letter to regulating agency to determine regulatory review period | 08 May, 2024 | US8993640 |
| Second letter to regulating agency to determine regulatory review period | 08 May, 2024 | US8440854 |
| Second letter to regulating agency to determine regulatory review period | 08 May, 2024 | US9701709 |
| Second letter to regulating agency to determine regulatory review period | 08 May, 2024 | US8124799 |
| Second letter to regulating agency to determine regulatory review period | 08 May, 2024 | US9670147 |
| Second letter to regulating agency to determine regulatory review period | 08 May, 2024 | US11091430 |
|
Recordation of Patent Grant Mailed
Critical
| 05 Mar, 2024 | US11919838 |
| Patent eGrant Notification | 05 Mar, 2024 | US11919838 |
| Mail Patent eGrant Notification | 05 Mar, 2024 | US11919838 |
|
Email Notification
Critical
| 05 Mar, 2024 | US11919838 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 05 Mar, 2024 | US11919838 |
| Recordation of Patent eGrant | 05 Mar, 2024 | US11919838 |
|
Email Notification
Critical
| 15 Feb, 2024 | US11919838 |
|
Issue Notification Mailed
Critical
| 14 Feb, 2024 | US11919838 |
| Letter from FDA or Dept of Agriculture re PTE application | 30 Jan, 2024 | US8124799 |
Reata Pharms's Family Patents
Reata Pharms drugs have patent protection in a total of 34 countries. It's US patent count contributes only to 20.4% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Reata Pharms Drug List
Given below is the complete list of Reata Pharms's drugs and the patents protecting them.
1. Skyclarys
Skyclarys is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8993640 | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
24 Apr, 2033
(8 years from now)
| Active |
| US9701709 | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
24 Apr, 2033
(8 years from now)
| Active |
| US8124799 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
03 Dec, 2029
(4 years from now)
| Active |
| US11091430 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 |
20 Apr, 2029
(4 years from now)
| Active |
| US11919838 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
20 Apr, 2029
(4 years from now)
| Active |
| US8440854 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino acid and other modifications at C-17 |
20 Apr, 2029
(4 years from now)
| Active |
| US9670147 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
20 Apr, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Skyclarys's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List